Published on October 19, 2009 at 9:14 AM
Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced favorable safety and efficacy data following administration of a second course (R2) of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis (RA). These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b (15002) RA study of TRU-015. Pfizer Inc. and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including RA.
Data from the open-label re-treatment phase of the Phase 2b study demonstrate that repeat administration with TRU-015 is generally well-tolerated and results in sustained improvement in the signs and symptoms of RA. Results were presented at the 2009 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (AHRP) Annual Scientific Meeting in Philadelphia. A copy of the poster is available in the investor section of Trubion's website (http://investors.trubion.com/index.cfm).
SOURCE Trubion Pharmaceuticals, Inc.